Anna Sureda, MD, PhD of Hospital Duran i Reynals, Barcelona, Spain discusses the clinical indications for the use of brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma. Dr Sureda explains that some patients are primary refractory to first-line therapy and some patients relapse after achieving complete remission (CR). These patients are treated with an autologous stem cell transplant but this approach is only curative for 50% of patients who are candidates for transplant. Therefore, new treatment strategies are required for these patients. Brentuximab vedotin is approved for Hodgkin lymphoma patients who relapse after an autologous stem cell transplantation. It is also approved for patients who have failed two lines of chemotherapy and who are not eligible for stem cell transplantation. Further, brentuximab vedotin can be used to consolidate patients who are candidates for autologous stem cell transplantation but have a high risk of relapse after the transplant. The benefit of using brentuximab vedotin consolidation in this context was shown in the AETHERA trial (NCT01100502). Recorded at the International Conference on Malignant Lymphoma (ICML) 2017 held in Lugano, Switzerland.